EOLS
insider transactionsEvolus, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-163.5K
0 buy · 163.5K sell
Net value · 365d
-$796.9K
$0 in · $796.9K out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
4
0 buy · 163.5K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Sell·S
David Moatazedi KEY
President & Chief Executive O… · 10b5-1
$64.9K
13.7K sh · $4.75
Own -2%
-
Sell·S
Officer
$14.8K
3.1K sh · $4.75
Own -1%
-
Sell·S
David Moatazedi KEY
President and Chief Executive… · 10b5-1
$570.6K
116.7K sh · $4.89
Own -16%
-
Sell·S
Chief Medical Officer and Hea… · 10b5-1
$146.6K
30.0K sh · $4.89
Own -7%
-
Exercise·M
David Moatazedi KEY
President and Chief Executive… · 10b5-1
$0
67.5K sh
Own New
-
Exercise·M
David Moatazedi KEY
President and Chief Executive… · 10b5-1
$0
67.5K sh
Own +10%
-
Exercise·M
Chief Medical Officer and Hea… · 10b5-1
$0
8.8K sh
Own New
-
Exercise·M
Chief Medical Officer and Hea… · 10b5-1
$0
8.8K sh
Own +2%
-
Grant·A
Director
$0
45.6K sh
Own +142%
-
Grant·A
Director
$0
45.6K sh
Own +51%
-
Grant·A
Tatjana Mitchell KEY
Chief Financial Officer
$0
177.5K sh
Own New
-
Grant·A
Tatjana Mitchell KEY
Chief Financial Officer
$0
121.5K sh
Own New
-
Grant·A
Tatjana Mitchell KEY
Chief Financial Officer
$0
121.5K sh
Own +116%
-
Grant·A
Director
$0
45.6K sh
Own +90%
-
Grant·A
David Moatazedi KEY
President and Chief Executive…
$0
457.5K sh
Own New
-
Grant·A
David Moatazedi KEY
President and Chief Executive…
$0
626.4K sh
Own New
-
Grant·A
David Moatazedi KEY
President and Chief Executive…
$0
313.2K sh
Own +88%
-
Grant·A
Director
$0
45.6K sh
Own +17%
-
Grant·A
Director
$0
45.6K sh
Own +110%
-
Grant·A
Chief Medical Officer and Hea…
$0
138.6K sh
Own New
-
Grant·A
Chief Medical Officer and Hea…
$0
94.9K sh
Own New
-
Grant·A
Chief Medical Officer and Hea…
$0
94.9K sh
Own +27%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Mar 20, 2026 | David Moatazedi KEY 10b5-1 | Sell S | 13.7K | $64.9K |
| Mar 20, 2026 | Rui Avelar | Sell S | 3.1K | $14.8K |
| Mar 17, 2026 | David Moatazedi KEY 10b5-1 | Sell S | 116.7K | $570.6K |
| Mar 17, 2026 | Rui Avelar 10b5-1 | Sell S | 30.0K | $146.6K |
| Mar 16, 2026 | David Moatazedi KEY 10b5-1 | Exercise M | 67.5K | $0 |
| Mar 16, 2026 | David Moatazedi KEY 10b5-1 | Exercise M | 67.5K | $0 |
| Mar 16, 2026 | Rui Avelar 10b5-1 | Exercise M | 8.8K | $0 |
| Mar 16, 2026 | Rui Avelar 10b5-1 | Exercise M | 8.8K | $0 |
| Feb 17, 2026 | Karah Herdman Parschauer | Grant A | 45.6K | $0 |
| Feb 17, 2026 | Brady Stewart | Grant A | 45.6K | $0 |
| Feb 17, 2026 | Tatjana Mitchell KEY | Grant A | 177.5K | $0 |
| Feb 17, 2026 | Tatjana Mitchell KEY | Grant A | 121.5K | $0 |
| Feb 17, 2026 | Tatjana Mitchell KEY | Grant A | 121.5K | $0 |
| Feb 17, 2026 | Albert G White III | Grant A | 45.6K | $0 |
| Feb 17, 2026 | David Moatazedi KEY | Grant A | 457.5K | $0 |
| Feb 17, 2026 | David Moatazedi KEY | Grant A | 626.4K | $0 |
| Feb 17, 2026 | David Moatazedi KEY | Grant A | 313.2K | $0 |
| Feb 17, 2026 | Vikram Malik | Grant A | 45.6K | $0 |
| Feb 17, 2026 | David N Gill | Grant A | 45.6K | $0 |
| Feb 17, 2026 | Rui Avelar | Grant A | 138.6K | $0 |
| Feb 17, 2026 | Rui Avelar | Grant A | 94.9K | $0 |
| Feb 17, 2026 | Rui Avelar | Grant A | 94.9K | $0 |
About EOLS insider trading
This page tracks insider transactions for Evolus, Inc. (EOLS) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.